Literature DB >> 2783154

Selective delivery of drugs to macrophages through a highly specific receptor. An efficient chemotherapeutic approach against leishmaniasis.

G Chaudhuri1, A Mukhopadhyay, S K Basu.   

Abstract

Methotrexate (Mtx) conjugated with maleylated bovine serum albumin (Mtx-MBSA) was taken up and degraded by cultured hamster peritoneal macrophages through the polyanion binding site for acetylated low density lipoprotein. Mtx-MBSA also eliminated intracellular amastigotes of Leishmania donovani in cultured hamster peritoneal macrophages about three times more efficiently than free Mtx. The antileishmanial effect of Mtx-MBSA on parasitized macrophages was blocked by MBSA, lysosomal inhibitors (chloroquine and monensin), and metabolic antagonists of Mtx (folic and folinic acids). The primary sites of accumulation of radioactivity of injected 125I-labeled Mtx-MBSA were the macrophage rich tissues, viz. liver and spleen. These results suggest that Mtx-MBSA would ensure rapid and effective killing of intracellular parasites harbored by macrophages. Furthermore, these results also indicate the feasibility of a general approach for rapid intracellular delivery of desired agents to macrophages for various purposes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783154     DOI: 10.1016/0006-2952(89)90007-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Antileishmanial drug targeting through glycosylated polymers specifically internalized by macrophage membrane lectins.

Authors:  E Nègre; M L Chance; S Y Hanboula; M Monsigny; A C Roche; R M Mayer; M Hommel
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  Scavenger-receptor-mediated delivery of daunomycin elicits selective toxicity towards neoplastic cells of macrophage lineage.

Authors:  A Mukhopadhyay; B Mukhopadhyay; R K Srivastava; S K Basu
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

3.  Increased efficacy of antileishmanial antisense phosphorothioate oligonucleotides in Leishmania amazonensis overexpressing ribonuclease H.

Authors:  M Mishra; J R Bennett; G Chaudhuri
Journal:  Biochem Pharmacol       Date:  2001-02-15       Impact factor: 5.858

4.  Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite.

Authors:  G Chaudhuri
Journal:  Biochem Pharmacol       Date:  1997-02-07       Impact factor: 5.858

5.  Enhanced activity of antisense phosphorothioate oligos against leishmania amastigotes: augmented uptake of oligo, ribonuclease H activation, and efficient target intervention under altered growth conditions.

Authors:  M Mishra; J M Porter-Kelley; P K Singh; J R Bennett; G Chaudhuri
Journal:  Biochem Pharmacol       Date:  2001-09-01       Impact factor: 5.858

Review 6.  Beyond oncology--application of HPMA copolymers in non-cancerous diseases.

Authors:  Xin-Ming Liu; Scott C Miller; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

7.  Possible mechanism of miltefosine-mediated death of Leishmania donovani.

Authors:  Navin K Verma; Chinmoy S Dey
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.

Authors:  M Nishikawa; A Kamijo; T Fujita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

9.  Killing of intracellular Mycobacterium tuberculosis by receptor-mediated drug delivery.

Authors:  S Majumdar; S K Basu
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

10.  Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages.

Authors:  G Cantos; C L Barbieri; M Iacomini; P A Gorin; L R Travassos
Journal:  Biochem J       Date:  1993-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.